DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: Therefore, the overall conclusion and recommendations that can be drawn from this study are that clinicians should consider performing additional RNA- or DNA-based evaluations for any cases in which dysferlinopathy is highly suspected based on clinical, genetic, and/or protein evaluations but who do not have two clearly P/LP DYSF variants identified after DNA sequencing.